In vitro profile of the new inhaled pan-JAK inhibitor LAS194046Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systemsSource: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
Enhanced anti-inflammatory gene expression in humans following inhaled budesonide Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013
In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Late Breaking Abstract - Anti-inflammatory and anti-fibrotic effect of novel, pan-PDE inhibitors in human bronchial epithelial cells Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020
Prediction of human lung PK for AZD7624, an inhaled P38 inhibitor for the treatment of COPD Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Anti-inflammatory effects of resveratrol analogues in cellular models of airway inflammation Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
Tiotropium and olodaterol exert anti-proliferative effects on pulmonary fibroblasts of asthmatic patients in vitro Source: Annual Congress 2013 –Airway smooth muscle and cell biology Year: 2013
A combination of thyme and ivy exerts potent anti-inflammatory and mucus-normalizing activity in vivo and inhibits 5-LO and PDE4 Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
Demonstration of anti-inflammatory properties of an inhaled p38 inhibitor AZD7624 Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015
Influence of nebulized drugs on ciliary activity in vitro Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013
Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021
Pirfenidone induced inhibition of p38 downregulates procoagulant microparticle generation by human alveolar epithelia cells Source: International Congress 2016 – Translational studies in lung disease Year: 2016
cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
Synergistic effect of human tubal mesenchymal stem cell (htMSCs) and low level laser (LLL) therapy significantly reduces experimental COPD in mice Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014